MCID: PFF001
MIFTS: 69

Pfeiffer Syndrome malady

Categories: Genetic diseases, Rare diseases, Infectious diseases, Eye diseases, Bone diseases, Fetal diseases, Skin diseases, Endocrine diseases

Aliases & Classifications for Pfeiffer Syndrome

About this section
Sources:
49OMIM, 33MalaCards, 10Disease Ontology, 11diseasecard, 68Wikipedia, 45NIH Rare Diseases, 23Genetics Home Reference, 47Novoseek, 12DISEASES, 51Orphanet, 67UniProtKB/Swiss-Prot, 65UMLS, 36MeSH, 35MedlinePlus, 2CDC, 24GTR, 42NCIt, 59SNOMED-CT, 27ICD10, 29ICD9CM, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet, 34MedGen, 61The Human Phenotype Ontology
See all MalaCards sources

Aliases & Descriptions for Pfeiffer Syndrome:

Name: Pfeiffer Syndrome 49 33 10 11 68 45 23 47 12 51 67 65
Infectious Mononucleosis 33 10 47 12 36 35 2 65
Acs5 45 23 51 67
Craniofacial-Skeletal-Dermatologic Dysplasia 49 11 23
Pfeiffer Type Acrocephalosyndactyly 45 65
Acrocephalosyndactyly, Type V 68 23
Acrocephalosyndactyly Type 5 51 67
Pfeiffer's Disease 10 24
Noack Syndrome 68 23
 
Acs V 23 67
Gammaherpesviral Mononucleosis 10
Acrocephalosyndactylia Type V 10
Acrocephalosyndactyly, Type 5 45
Filatov's Disease 10
Monocytic Angina 10
Glandular Fever 10
Mononucleosis 10
Ps 67

Characteristics:

Orphanet epidemiological data:

51
pfeiffer syndrome:
Inheritance: Autosomal dominant; Prevalence: 1-9/100000 (Europe); Age of onset: Antenatal,Neonatal; Age of death: any age

HPO:

61
pfeiffer syndrome:
Inheritance: autosomal dominant inheritance


Classifications:



External Ids:

OMIM49 101600
Disease Ontology10 DOID:14705, DOID:8568
ICD1027 B27, B27.0, B27.9
ICD9CM29 075
Orphanet51 710
ICD10 via Orphanet28 Q87.0
MESH via Orphanet37 C538582
UMLS via Orphanet66 C2931888
UMLS65 C0220658, C0021345, C2931888

Summaries for Pfeiffer Syndrome

About this section
OMIM:49 Pfeiffer syndrome is an autosomal dominant craniosynostosis syndrome with characteristic anomalies of the hands and... (101600) more...

MalaCards based summary: Pfeiffer Syndrome, also known as infectious mononucleosis, is related to pfeiffer syndrome type 1, 2 and 3 and pfeiffer syndrome type 1, and has symptoms including hypoplasia of the zygomatic bone, abnormality of thumb phalanx and ptosis. An important gene associated with Pfeiffer Syndrome is FGFR2 (Fibroblast Growth Factor Receptor 2), and among its related pathways are Central carbon metabolism in cancer and Alzheimers Disease Pathway. Affiliated tissues include skull, bone and t cells, and related mouse phenotypes are hearing/vestibular/ear and embryo.

Disease Ontology:10 An acrocephalosyndactylia that has material basis in mutations in the FGFR1 and FGFR2 gene which results in premature fusion located in skull.

NIH Rare Diseases:45 Pfeiffer syndrome is a disorder that affects the development of the bones in the skull, hands and feet. signs and symptoms can include craniosynostosis, which prevents normal skull growth and affects the shape of the head and face; distinctive facial features including bulging and wide-set eyes, a high forehead, an underdeveloped upper jaw, and a beaked nose; hearing loss; and dental problems. other features may include broad and deviated thumbs and great toes; brachydactyly; and syndactyly. it is caused by mutations in the fgfr1 or fgfr2 genes and is inherited in an autosomal dominant manner. pfeiffer syndrome is divided into 3 subtypes (types 1, 2 and 3) based on the presence and severity of specific features. management typically includes various surgical interventions. last updated: 12/1/2015

UniProtKB/Swiss-Prot:67 Pfeiffer syndrome: A syndrome characterized by the association of craniosynostosis, broad and deviated thumbs and big toes, and partial syndactyly of the fingers and toes. Three subtypes are known: mild autosomal dominant form (type 1); cloverleaf skull, elbow ankylosis, early death, sporadic (type 2); craniosynostosis, early demise, sporadic (type 3).

MedlinePlus:35 Infectious mononucleosis, or "mono", is an infection usually caused by the epstein-barr virus. the virus spreads through saliva, which is why it's sometimes called "kissing disease." mono occurs most often in teens and young adults. however, you can get it at any age. symptoms of mono include fever sore throat swollen lymph glands sometimes you may also have a swollen spleen. serious problems are rare. a blood test can show if you have mono. most people get better in two to four weeks. however, you may feel tired for a few months afterward. treatment focuses on helping symptoms and includes medicines for pain and fever, warm salt water gargles and plenty of rest and fluids.

CDC:2 Epstein-Barr virus, or EBV, is one of the most common human viruses in the world. It spreads primarily through saliva. EBV can cause infectious mononucleosis, also called mono, and other illnesses. Most people will get infected with EBV in their lifetime and will not have any symptoms. Mono caused by EBV is most common among teens and adults…

Genetics Home Reference:23 Pfeiffer syndrome is a genetic disorder characterized by the premature fusion of certain skull bones (craniosynostosis). This early fusion prevents the skull from growing normally and affects the shape of the head and face. Pfeiffer syndrome also affects bones in the hands and feet.

Wikipedia:68 Pfeiffer syndrome is a very rare genetic disorder characterized by the premature fusion of certain bones... more...

Related Diseases for Pfeiffer Syndrome

About this section

Diseases in the Pfeiffer Syndrome family:

Pfeiffer Syndrome Type 1 Pfeiffer Syndrome Type 1, 2 and 3
Pfeiffer Syndrome Type 3

Diseases related to Pfeiffer Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 139)
idRelated DiseaseScoreTop Affiliating Genes
1pfeiffer syndrome type 1, 2 and 334.1FGFR1, FGFR2
2pfeiffer syndrome type 112.3
3winkelman bethge pfeiffer syndrome12.2
4pfeiffer syndrome type 312.2
5lymphoproliferative syndrome, x-linked, 111.9
6proteus syndrome, somatic11.5
7cardiocranial syndrome11.4
8polydactyly, preaxial type ii11.3
9pituitary hormone deficiency, combined, 311.2
10mesomelic dwarfism, reinhardt-pfeiffer type11.2
11werner syndrome10.8
12scott syndrome10.7
13fibrogenesis imperfecta ossium10.4ALPL, BGLAP
14plagiocephaly and x-linked mental retardation10.4FGFR1, FGFR2, FGFR3
15marcus gunn phenomenon10.3ALPL, BGLAP, RUNX2
16flna-related periventricular nodular heterotopia10.3FGFR1, FGFR2, FGFR3
17hypogonadotropic hypogonadism 2 with or without anosmia10.3FGFR1, FGFR2, FGFR3
18bone structure disease10.3ALPL, BGLAP, RUNX2
19rectosigmoid junction neoplasm10.3BGLAP, FGFR1, SP7
20apert syndrome10.3FGFR1, FGFR2, FGFR3
21crouzon syndrome with acanthosis nigricans10.3FGFR1, FGFR2, FGFR3
22thanatophoric dysplasia, type i10.3FGFR1, FGFR2, FGFR3
23perlman syndrome10.3
24eosinophilic pneumonia10.3ALPL, BGLAP, RUNX2
25autosomal dominant microcephaly10.3COL1A1, COL3A1
26breast cancer10.3
27neuronitis10.3
28neuropathy10.3
29vulvovaginal candidiasis10.3FGFR1, FGFR2, SP7
30beare-stevenson cutis gyrata syndrome10.3FGFR1, FGFR2, FGFR3
31distal monosomy 1q10.3FGFR3, TWIST1
32bone development disease10.2ALPL, BGLAP, RUNX2, SP7
33arthritis10.2
34leukemia10.2
35adenocarcinoma10.2
36prostate cancer10.2
37small cell cancer of the lung, somatic10.2ALPL, BGLAP, RUNX2, SP7
38darier disease10.2COL1A1, COL3A1, FGFR3, RUNX2
39bartholin's gland adenocarcinoma10.1ALPL, TNFRSF8
40bladder cancer, somatic10.1FGFR1, FGFR2, FGFR3, TWIST1
41chromosomal disease10.1ALPL, BGLAP, COL1A1, RUNX2, SP7
42botulism10.1FGFR1, FGFR2, FGFR3, TWIST1
43diverticulitis of colon10.1FGF10, FGFR1, FGFR2, FGFR3
44giant cell glioblastoma10.1FGFR1, FGFR3, TWIST1
45rheumatoid arthritis10.1
46myocardial infarction10.1
47asthma10.1
48tay-sachs disease10.1
49pulmonary hypertension10.1
50acute myocardial infarction10.1

Graphical network of the top 20 diseases related to Pfeiffer Syndrome:



Diseases related to pfeiffer syndrome

Symptoms for Pfeiffer Syndrome

About this section

Symptoms by clinical synopsis from OMIM:

101600

Clinical features from OMIM:

101600

Symptoms:

 51 (show all 23)
  • flat cheek bones/malar hypoplasia
  • ptosis
  • broad/bifid thumb
  • autosomal dominant inheritance
  • turricephaly/oxycephaly/acrocephaly
  • high forehead
  • hypertelorism
  • broad nasal root
  • short hand/brachydactyly
  • syndactyly of fingers/interdigital palm
  • symphalangy of fingers
  • clinodactyly of fifth finger
  • flat face
  • facial structural asymmetry/facial hemiatrophy/facial hemihypertrophy
  • prognathism/prognathia
  • mouth held open
  • short philtrum
  • high vaulted/narrow palate
  • short neck
  • lordosis
  • carpal bones fusion/synostosis
  • hip dislocation/dysplasia/coxa valga/coxa vara/coxa plana
  • short stature/dwarfism/nanism

HPO human phenotypes related to Pfeiffer Syndrome:

(show all 48)
id Description Frequency HPO Source Accession
1 hypoplasia of the zygomatic bone hallmark (90%) HP:0010669
2 abnormality of thumb phalanx hallmark (90%) HP:0009602
3 ptosis hallmark (90%) HP:0000508
4 symphalangism affecting the phalanges of the hand typical (50%) HP:0009773
5 finger syndactyly typical (50%) HP:0006101
6 clinodactyly of the 5th finger typical (50%) HP:0004209
7 brachydactyly syndrome typical (50%) HP:0001156
8 wide nasal bridge typical (50%) HP:0000431
9 high forehead typical (50%) HP:0000348
10 hypertelorism typical (50%) HP:0000316
11 synostosis of carpal bones occasional (7.5%) HP:0005048
12 short stature occasional (7.5%) HP:0004322
13 hyperlordosis occasional (7.5%) HP:0003307
14 abnormality of the hip bone occasional (7.5%) HP:0003272
15 short neck occasional (7.5%) HP:0000470
16 facial asymmetry occasional (7.5%) HP:0000324
17 short philtrum occasional (7.5%) HP:0000322
18 mandibular prognathia occasional (7.5%) HP:0000303
19 malar flattening occasional (7.5%) HP:0000272
20 open mouth occasional (7.5%) HP:0000194
21 abnormality of the palate occasional (7.5%) HP:0000174
22 broad thumb HP:0011304
23 broad hallux HP:0010055
24 shortening of all middle phalanges of the fingers HP:0006110
25 finger syndactyly HP:0006101
26 cartilaginous trachea HP:0005347
27 depressed nasal bridge HP:0005280
28 coronal craniosynostosis HP:0004440
29 short middle phalanx of toe HP:0003795
30 short nose HP:0003196
31 elbow ankylosis HP:0003070
32 humeroradial synostosis HP:0003041
33 bronchomalacia HP:0002780
34 cloverleaf skull HP:0002676
35 arnold-chiari malformation HP:0002308
36 intellectual disability HP:0001249
37 dental crowding HP:0000678
38 shallow orbits HP:0000586
39 downslanted palpebral fissures HP:0000494
40 strabismus HP:0000486
41 choanal atresia HP:0000453
42 choanal stenosis HP:0000452
43 hypoplasia of the maxilla HP:0000327
44 hypertelorism HP:0000316
45 mandibular prognathia HP:0000303
46 brachyturricephaly HP:0000244
47 hydrocephalus HP:0000238
48 high palate HP:0000218

Drugs & Therapeutics for Pfeiffer Syndrome

About this section

Drugs for Pfeiffer Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50)    (show all 55)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1AntibodiesPhase 3, Phase 14477
2ImmunoglobulinsPhase 3, Phase 14477
3Immunoglobulin GPhase 3146
4
Dexamethasoneapproved, investigationalPhase 2190950-02-25743
Synonyms:
(3H)-Dexamethasone
.delta.(sup 1)-9-.alpha.-Fluoro-16-.alpha.-methylcortisol
.gamma.corten
1-Dehydro-16.alpha.-methyl-9.alpha.-fluorohydrocortisone
1-Dehydro-16alpha -methyl-9alpha -fluorohydrocortisone
1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone
1-Dehydro-16α-methyl-9α-fluorohydrocortisone
137098-19-2
16-alpha-Methyl-9-alpha-fluoro-1-dehydrocortisol
16-alpha-Methyl-9-alpha-fluoro-delta(sup 1)-hydrocortisone
16-alpha-Methyl-9-alpha-fluoro-delta1-hydrocortisone
16-alpha-Methyl-9-alpha-fluoroprednisolone
16.alpha.-Methyl-9.alpha.-fluoro-1-dehydrocortisol
16.alpha.-Methyl-9.alpha.-fluoroprednisolone
16alpha -Methyl-9alpha -fluoro-1-dehydrocortisol
16alpha -Methyl-9alpha -fluoroprednisolone
16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol
16alpha-Methyl-9alpha-fluoro-delta(sup 1)-hydrocortisone
16alpha-Methyl-9alpha-fluoroprednisolone
16α-Methyl-9α-fluoro-1-dehydrocortisol
23495-06-9
31375_FLUKA
46165_FLUKA
46165_RIEDEL
50-02-2
8054-59-9
9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
9-Fluoro-11alpha -methylpregna-1,4-diene-3,20-dione
9-Fluoro-16-methylprednisolone
9-alpha-Fluoro-16-alpha-methylprednisolone
9.alpha.-Fluoro-16.alpha.-methylprednisolone
906422-84-2
9A-FLUORO-16BETA-METHYLPREDNISOLONE
9alpha -Fluoro-16alpha -methylprednisolone
9alpha-Fluoro-16alpha-methylprednisolone
9alpha-fluoro-16alpha-methyl-Prednisolone
9α-Fluoro-16α-methylprednisolone
AC-11056
AC1L1L1H
AC1Q29DM
AI3-50934
Adexone
Aeroseb-D
Aeroseb-Dex
Aeroseb-dex
Ak Dex Oph Otic Soln 0.1%
Alcon Brand of Dexamethasone
Anaflogistico
Aphtasolon
Aphthasolone
Apo-dexamethasone
Auxiron
Azimycin (veterinary)
Azium
Azium (Veterinary)
Azium (veterinary)
BIDD:ER0494
BIDD:PXR0060
BRD-K38775274-001-02-3
BRD-K38775274-001-06-4
BSPBio_000995
Baycadron
Bisu DS
Bisu Ds
C15643
C22H29FO5
CCRIS 7067
CHEBI:41879
CHEMBL384467
CID5743
CPD-10549
CPD001227192
Calonat
Corson
Corsone
Cortisumman
D00292
D003907
D1756_SIGMA
D4902_SIGMA
D6645_SIGMA
D8893_SIGMA
D9184_SIGMA
DB01234
DEX
DEXA
DEXONE 0.5
DEXONE 0.75
DEXONE 1.5
DEXONE 4
DXM
DXMS
Decacort
Decacortin
Decaderm
Decadron
Decadron (TN)
Decadron Tablets, Elixir
Decadron, Dexamethasone
Decadron-LA
Decadron-La
Decagel
Decaject
Decaject L.A.
Decaject-L.A.
Decalix
Decameth
Decasone
Decaspray
Dectancyl
Dekacort
Delta1-9alpha-Fluoro-16alpha-methylcortisol
Deltafluorene
Dergramin
Deronil
Desadrene
Desametasone
Desametasone [DCIT]
Desametasone [Dcit]
Desamethasone
Desameton
Deseronil
Dex-Ide
Dex-ide
Dexa
Dexa Mamallet
Dexa mamallet
Dexa-Cortidelt
Dexa-Cortisyl
Dexa-Mamallet
Dexa-Scheroson
Dexa-Sine
Dexa-cortidelt
Dexa-cortisyl
Dexa-scheroson
Dexa-sine
Dexacen-4
Dexacidin
Dexacort
Dexacortal
Dexacortin
Dexadeltone
Dexafarma
Dexair
Dexalona
Dexaltin
Dexametasona
Dexametasona [INN-Spanish]
Dexametasone
Dexameth
Dexamethansone
 
Dexamethasone
Dexamethasone (JP15/USP/INN)
Dexamethasone Acetate
Dexamethasone Alcohol
Dexamethasone Base
Dexamethasone Intensol
Dexamethasone Sodium Phosphate
Dexamethasone [INN:BAN:JAN]
Dexamethasone acetate
Dexamethasone alcohol
Dexamethasone base
Dexamethasone intensol
Dexamethasone sodium phosphate
Dexamethasone-omega
Dexamethasonum
Dexamethasonum [INN-Latin]
Dexamethazone
Dexamethsone
Dexamonozon
Dexapolcort
Dexapos
Dexaprol
Dexason
Dexasone
Dexasone 0.5mg
Dexasone 0.75mg
Dexasone 4mg
Dexasporin
Dexinolon
Dexinoral
Dexone
Dexone 0.5
Dexone 0.75
Dexone 1.5
Dexone 4
Dexonium
Dexpak
Dextelan
Dezone
Dinormon
Dxms
ECR Brand of Dexamethasone
EINECS 200-003-9
FT-0080377
Fluormethylprednisolone
Fluormone
Fluorocort
Fortecortin
Foy Brand of Dexamethasone
Gammacorten
HL-dex
HMS1792A17
HMS1990A17
HMS2089N13
HSDB 3053
Hexadecadrol
Hexadrol
Hexadrol Elixir
Hexadrol Tablets
Hexadrol elixir
Hl-Dex
Hl-dex
I06-1196
ICN Brand of Dexamethasone
IontoDex
Isopto-Dex
Isopto-dex
LS-7300
Lokalison F
Lokalison f
Loverine
Luxazone
MK 125
MLS001055412
MLS001332507
MLS001332508
Maxidex
Maxidex Ont 0.1%
Maxidex Sus 0.1%
Maxitrol
Mediamethasone
Merck Brand of Dexamethasone
Merz Brand 1 of Dexamethasone
Merz Brand 2 of Dexamethasone
Methylfluorprednisolone
Mexidex
Millicorten
MolMap_000018
MolPort-003-846-433
Mymethasone
NCGC00091019-01
NCGC00091019-02
NCGC00091019-03
NCGC00091019-04
NCGC00091019-05
NCI60_003067
NSC 34521
NSC34521
Naquasone (veterinary)
Neomycin and polymyxin b sulfates and dexamethasone
Neomycin and polymyxin b sulphates and dexamethasone
OTO-104
Ocu-Trol
Ocu-trol
Oradexon
Ozurdex
PHL-dexamethasone
PMS-dexamethasone
Pet Derm III
Pet Derm Iii
Pet derm III
Pet-Derm Iii
Pms Dexamethasone Elixir 0.5mg/5ml
Policort
Posurdex
Prednisolon F
Prednisolon f
Prednisolone F
Prednisolone f
Prodex
S1322_Selleck
SAM002548948
SGCUT00126
SK-Dexamethasone
SK-dexamethasone
SMP1_000092
SMR000857119
SMR001227192
ST50307091
Sandoz dexamethasone
Sk-Dexamethasone
Spectrum5_002019
Spoloven
Sunia Sol D
Sunia sol D
Superprednol
TL8003317
Tobradex
Tobramycin and dexamethasone
Tresaderm (veterinary)
Turbinaire
UNII-7S5I7G3JQL
Visumetazone
WLN: L E5 B666 OV KU MUTJ A1 BF CQ E1 FV1Q FQ G1
ZINC03875332
alpha -Fluoro-16-alpha -methylcortisol
delta(Sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta(sup 1)-9-alpha-Fluoro-16-alpha-methylcortisol
delta1-9alpha-Fluoro-16alpha-methylcortisol
dexamethasone
nchembio809-comp2
to_000038
5
CarboplatinapprovedPhase 2188541575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
6
PaclitaxelapprovedPhase 2262133069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
7
ponatinibapprovedPhase 229943319-70-824826799
Synonyms:
AP 24534
AP24534
 
Iclusig
Ponatinib Hydrochloride
Ponatinibum
ponatinib
8
Docetaxelapproved, investigational, Approved May 1996Phase 21844114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
9glucocorticoidsPhase 23896
10Gastrointestinal AgentsPhase 26401
11Hormone AntagonistsPhase 210002
12Tubulin ModulatorsPhase 24279
13AnalgesicsPhase 29358
14Albumin-Bound PaclitaxelPhase 22621
15Peripheral Nervous System AgentsPhase 218510
16Hormones, Hormone Substitutes, and Hormone AntagonistsPhase 29988
17HormonesPhase 211748
18Antineoplastic Agents, PhytogenicPhase 24294
19valacyclovirPhase 1, Phase 2101
20Dexamethasone acetatePhase 219091177-87-3
21Antiviral AgentsPhase 1, Phase 28071
22Anti-Infective AgentsPhase 1, Phase 217220
23AcyclovirPhase 1, Phase 2153
24Immunologic FactorsPhase 2, Phase 118483
25VaccinesPhase 26085
26BB 1101Phase 21909
27AntiemeticsPhase 23213
28Dexamethasone 21-phosphatePhase 21909
29Antineoplastic Agents, HormonalPhase 24256
30Antimitotic AgentsPhase 24296
31Anti-Inflammatory AgentsPhase 28478
32PONATINIB Phase 2
33Protein Kinase InhibitorsPhase 23162
34Liver ExtractsPhase 1, Phase 23572
35MitogensPhase 1, Phase 21386
36tyrosineNutraceuticalPhase 1, Phase 2596
37
NeomycinapprovedPhase 1421404-04-28378
Synonyms:
(1R,2R,3S,4R,6S)-4,6-diamino-2-{[3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranosyl]oxy}-3-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-alpha-D-glucopyranoside
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-[(1R,2R,3S,4R,6S)-4,6-diamino-2-[(2S,3R,4S,5R)-4-[(2R,3R,4R,5S,6S)-3-amino-6-(aminomethyl)-4,5-dihydroxyoxan-2-yl]oxy-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-3-hydroxycyclohexyl]oxyoxane-3,4-diol
11025-81-3
119-04-0
1393-86-8
1404-04-2
1405-10-3 (sulfate (salt))
4-18-00-07476 (Beilstein Handbook Reference)
72131_FLUKA
AB00443887
AC1L1QVH
Actilin
Actiline
Antibiotic 10676
Antibiotic produced by Streptomyces decaris. Neomycin B
Antibiotique
BDG-(1-4)CYY-(5-1)RIB-(3-1)IDG
BDG-(1-4)NEB-(5-1)RIB-(3-1)NED
BPBio1_000326
BRN 0101621
BSPBio_000296
C01737
C23H46N6O13
C25H50N6O13
CCRIS 5462
CHEBI:7508
CID8378
Caswell No. 595
D-Streptamine, O-2,6-diamino-2,6-dideoxy-.beta.-L-idopyranosyl-(1.->3)-O-.beta.-D-ribofuranosyl-(1->5)]-O-[2,6-diamino-2,6-dideoxy-.alpha.-D-glucopyranosyl-(1->4)]-2-deoxy
D05140
DB00452
DB00994
EINECS 204-292-2
EINECS 215-766-3
EPA Pesticide Chemical Code 006303
Endomixin
Enterfram
Fradiomycin
Fradiomycin B
Fradiomycinum
Framicetina
Framicetina [INN-Spanish]
Framycetin
Framycetin (INN)
Framycetin [INN:BAN:DCF]
Framycetine
Framycetine [INN-French]
Framycetinum
Framycetinum [INN-Latin]
Framygen
 
Fraquinol
HMS2089P15
HSDB 3242
LS-96091
LS-96095
MolPort-003-938-736
Myacine
Myacyne
Mycifradin
Myciguent
N1142_SIGMA
NCGC00179612-01
NEOMYCIN AND POLYMYXIN B SULFATES
NEOMYCIN B
NEOMYCIN SULFATE
NMY
Neo-Fradin
Neo-Rx
Neo-fradin
Neobiotic
Neobrettin
Neolate
Neomas
Neomcin
Neomicina
Neomicina [DCIT]
Neomin
Neomycin B Sulfate
Neomycin B sulfate
Neomycin Sulfate
Neomycin Sulphate
Neomycin solution
Neomycine
Neomycine [INN-French]
Neomycinum
Neomycinum [INN-Latin]
Nivemycin
PIMAVECORT
Prestwick3_000158
ST075177
Soframycin
Soframycin Ophthalmic
Soframycine
Theraplusplus Plus
Tuttomycin
UNII-4BOC774388
UNII-I16QD7X297
USAF CB-19
VONAMYCIN
Vonamycin powder V
neomycin
38
Cyclophosphamideapproved, investigationalPhase 1264350-18-0, 6055-19-22907
Synonyms:
(+-)-Cyclophosphamide
(-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
ASTA
ASTA B518
Asta B 518
B 518
B-518
BRN 0011744
BSPBio_002099
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
CID2907
CP
CPA
CTX
CY
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
Clafen
Claphene
Cycloblastin
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide anhydrous
Cyclophosphamide, (+-)-Isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
 
DivK1c_000246
EINECS 200-015-4
EU-0100238
Endoxan
Endoxan R
Endoxan-Asta
Endoxana
Endoxanal
Endoxane
Enduxan
Genoxal
HMS2090A12
HSDB 3047
Hexadrin
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
LS-1302
LS-99787
Ledoxina
Lopac-C-0768
Lopac0_000238
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI-C04900
NCI60_002097
NINDS_000246
NSC 26271
NSC-26271
NSC26271
NSC273033
NSC273034
Neosar
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra Waste Number U058
Rcra waste number U058
Revimmune
S1217_Selleck
SK 20501
SPBio_001071
STK177249
STOCK2S-91217
Semdoxan
Sendoxan
Senduxan
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
Spectrum_000858
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
cyclophosphamide
39
FludarabineapprovedPhase 1105921679-14-1, 75607-67-930751
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
2-F-ara-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoro-ara AMP
2-Fluoroadenine arabinoside 5'-monophosphate
21679-14-1
2F-Ara-AMP
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
AC1LCW8I
AC1Q51CF
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
CPD000058874
D07966
EINECS 244-525-5
F-Ara-A
FAMP
FT-0082766
FaraA
Fludara
 
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine 5'-monophosphate
Fludarabine Phosphate
Fludarabine [INN]
Fludarabine monophosphate
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
Fluradosa
Fluradosa (TN)
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
Oforta
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
40Alkylating AgentsPhase 13582
41Fludarabine phosphatePhase 1105930751
42Immunosuppressive AgentsPhase 110422
43AntimetabolitesPhase 19454
44Antirheumatic AgentsPhase 18496
45Antimetabolites, AntineoplasticPhase 15770
46Antineoplastic Agents, AlkylatingPhase 13406
47Pharmaceutical SolutionsPhase 17004
48Insulin, Globin Zinc4278
49insulin4278
50Autoantibodies117

Interventional clinical trials:

(show top 50)    (show all 54)
idNameStatusNCT IDPhase
1Acupuncture for Infectious Mononucleosis TrialCompletedNCT00598988Phase 2, Phase 3
2A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)RecruitingNCT01376778Phase 3
3Controlled Trial of Valacyclovir in Infectious MononucleosisCompletedNCT00274404Phase 1, Phase 2
4Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus InfectionCompletedNCT00575185Phase 1, Phase 2
5Evaluation of Safety, Immune-Response and Efficacy of GSK Biologicals’ EBV (Epstein Barr Virus) Vaccine (268664).CompletedNCT00430534Phase 2
6Accelerated Immunization to Induce Cytomegalovirus Immunity in Stem Cell DonorsCompletedNCT00353977Phase 2
7Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T LymphocytesCompletedNCT00953420Phase 2
8Efficacy and Safety of AZD4547 Versus Paclitaxel in Advanced Gastric or Gastro-oesophageal Junction Cancer PatientsCompletedNCT01457846Phase 2
9Sedation Management in Pediatric Patients Supported on Mechanical VentilationCompletedNCT00142766Phase 2
10ARMS - Rapidly Generated Multivirus-Specific CTLs for the Prophylaxis And Treatment of EBV, CMV, Adenovirus, HHV6, and BK VirusRecruitingNCT01570283Phase 1, Phase 2
11Phase 1/2 Study of ARQ 087 in Adult Subjects With Advanced Solid Tumors With FGFR Genetic AlterationsRecruitingNCT01752920Phase 1, Phase 2
12A Phase II, Single Arm Study of BGJ398 in Patients With Advanced CholangiocarcinomaRecruitingNCT02150967Phase 2
13Dovitinib for Gastric Cancer With FGFR2 AmplificationRecruitingNCT01719549Phase 2
14Ponatinib Hydrochloride in Treating Patients With Advanced Biliary Cancer With FGFR2 FusionsRecruitingNCT02265341Phase 2
15Epstein Barr Virus (EBV) Specific Cytotoxic T-Cells, Relapsed Lymphoma, ANGELCompletedNCT00058617Phase 1
16T-Lymphocytes in Treating Patients With Epstein-Barr Virus-Positive Nasopharyngeal Cancer, NPCCompletedNCT00609219Phase 1
17LMP1- and LMP2-Specific CTLs to Patients With EBV-Positive NPC (NATELLA)CompletedNCT00516087Phase 1
18Treating Severe Chronic Epstein-Barr Virus (EBV) Infection With EBV Specific Cytotoxic T Lymphocytes (CTLs)CompletedNCT00058591Phase 1
19Administration of Rapidly Generated Multivirus-specific Cytotoxic T-Lymphocytes (VIRAGE)CompletedNCT01070797Phase 1
20TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPCRecruitingNCT02065362Phase 1
21Cytotoxic T Cells to Treat Relapsed EBV-positive LymphomaRecruitingNCT01956084Phase 1
22Administration of Donor MultiTAA-Specific T Cells for ALLRecruitingNCT02475707Phase 1
23Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTALRecruitingNCT01333046Phase 1
24Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM)RecruitingNCT02494167Phase 1
25Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)RecruitingNCT02287311Phase 1
26Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALERecruitingNCT01555892Phase 1
27Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)RecruitingNCT02368951Phase 1
28Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated DiseasesActive, not recruitingNCT01447056Phase 1
29LMP-specific T-cells for Patients With Relapsed EBV-positive LymphomaActive, not recruitingNCT00062868Phase 1
30T-cells or EBV Specific CTLs, Advanced B-Cell NHL and CLLActive, not recruitingNCT00709033Phase 1
31EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ LymphomaActive, not recruitingNCT01192464Phase 1
32Autologous/Allogeneic TGFbeta-resistant LMP2A-specific CTL, Lymphoma (TGF-beta)Active, not recruitingNCT00368082Phase 1
33Blood T-Cells and EBV Specific CTLs Expressing GD-2 Specific Chimeric T Cell Receptors to Neuroblastoma PatientsActive, not recruitingNCT00085930Phase 1
34Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRATActive, not recruitingNCT00840853Phase 1
35Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin DiseaseTerminatedNCT00058773Phase 1
36Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's LymphomaTerminatedNCT00383097Phase 1
37LMP2a-Specific Cytotoxic T-Lymphocytes, Lymphoma (ACDAL)TerminatedNCT00082225Phase 1
38Genetic Studies of X-linked Lymphoproliferative DiseaseCompletedNCT00359411
39Prospective Study of Possible Infectious Disease - Associated Antigen Drive in Previously Untreated Indolent LymphomaCompletedNCT00582270
40Effects of Long-Term Treatment With Valaciclovir (Valtrex) on Epstein-Barr VirusCompletedNCT00005924
41Protein Studies of the Epstein-Barr Virus in Ethnically Diverse PopulationsCompletedNCT00070785
42Protein, Fiber, and Metabolic Syndrome - The PROFIMET StudyCompletedNCT00579657
43Effects of (1,3), (1,6)-Beta-D-glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic SyndromeCompletedNCT00403689
44Comparison of a Plant Protein Diet to a Animal Protein Diet Emphasized in Type 2 DiabeticsCompletedNCT02402985
45OPTIFIT-Optimal Fiber Trial for Diabetes PreventionCompletedNCT01681173
46Genetic Studies of Chronic Active Epstein-Barr DiseaseRecruitingNCT00032513
47HIV Indicator Diseases Across Europe StudyRecruitingNCT01681706
48Observing the Changes of Fibroblast Growth Factor 23 in Patients of Tumor Induced OsteomalaciaRecruitingNCT01660308
49Fibromyalgia Integrative Training for TeensRecruitingNCT01981096
50Comparative Autoantibody and Immunologic Cell Marker StudyEnrolling by invitationNCT02422875

Search NIH Clinical Center for Pfeiffer Syndrome


Cochrane evidence based reviews: infectious mononucleosis

Genetic Tests for Pfeiffer Syndrome

About this section

Anatomical Context for Pfeiffer Syndrome

About this section

MalaCards organs/tissues related to Pfeiffer Syndrome:

33
Bone, T cells, Eye, Monocytes, Testes, Spleen, B cells

FMA organs/tissues related to Pfeiffer Syndrome:

16
Skull

Animal Models for Pfeiffer Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Pfeiffer Syndrome:

38 (show all 23)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053779.0COL1A1, FGF10, FGF8, FGFR1, FGFR2, FGFR3
2MP:00053808.7ALPL, COL1A1, FGF10, FGF8, FGFR1, FGFR2
3MP:00028738.6COL1A1, FGF10, FGF8, FGFR1, FGFR2, FGFR3
4MP:00053918.6COL1A1, FGF10, FGF8, FGFR1, FGFR2, FGFR3
5MP:00053828.4ALPL, COL1A1, FGF10, FGF8, FGFR1, FGFR2
6MP:00053698.3ALPL, COL1A1, COL3A1, FGF10, FGF8, FGFR1
7MP:00053718.2ALPL, COL1A1, FGF10, FGF8, FGFR1, FGFR2
8MP:00053888.2ALPL, COL1A1, COL3A1, FGF10, FGF8, FGFR2
9MP:00053818.2ALPL, COL1A1, COL3A1, FGF10, FGF8, FGFR1
10MP:00107718.1CD40LG, COL1A1, COL3A1, FGF10, FGF7, FGFR1
11MP:00053867.7ALPL, COL1A1, FGF10, FGF7, FGF8, FGFR1
12MP:00053677.7CD40LG, COL1A1, CR2, FGF10, FGF7, FGF8
13MP:00053797.6ALPL, CD40LG, COL1A1, FGF10, FGF8, FGFR1
14MP:00053897.5ALPL, CD40LG, COL1A1, FGF10, FGF7, FGF8
15MP:00053847.5ALPL, CD40LG, COL1A1, COL3A1, FGF10, FGF8
16MP:00036317.2ALPL, CD40LG, COL1A1, FGF10, FGF7, FGF8
17MP:00053907.0ALPL, CD40LG, COL1A1, FGF10, FGF8, FGFR1
18MP:00053786.9ALPL, COL1A1, COL3A1, FGF10, FGF8, FGFR1
19MP:00053856.8ALPL, CD40LG, COL1A1, COL3A1, FGF10, FGF8
20MP:00053766.2ALPL, CD40LG, COL1A1, COL3A1, CR2, FGF10
21MP:00107685.7ALPL, CD40LG, COL1A1, COL3A1, CR2, FGF10
22MP:00053875.5ALPL, CD40LG, COL1A1, COL3A1, CR2, FGF10
23MP:00053975.2ALPL, CD40LG, COL1A1, CR2, FGF10, FGF7

Publications for Pfeiffer Syndrome

About this section

Articles related to Pfeiffer Syndrome:

(show top 50)    (show all 111)
idTitleAuthorsYear
1
Cardiogenic Shock From Coronary Compression: A Difficult Diagnosis But Easy Fix. (27000612)
2016
2
Frequency and epidemiologic aspects of male infertility. (25871021)
2015
3
Factor XIII-A subunit Val34Leu polymorphism and risk of venous thromboembolism in young adults]. (26035561)
2015
4
Follow-up of high-risk HPV positive women by combined cytology and bi-marker CADM1/MAL methylation analysis on cervical scrapes. (25667975)
2015
5
microRNA-21 mediates epithelial-mesenchymal transition of human hepatocytes via PTEN/Akt pathway. (25661333)
2015
6
OPRM1 polymorphism and lifetime suicide attempts among stabilized, methadone-maintained outpatients. (24813900)
2014
7
Causes, evaluation, and consequences of eosinophilic esophagitis. (24117638)
2013
8
Insulinoma of genetic aetiology. (23769271)
2013
9
Impact of insulin resistance on silent and ongoing myocardial damage in normal subjects: the Takahata study. (23093954)
2012
10
Advanced treatment modalities for vitiligo. (22288899)
2012
11
Protean presentation and multiple challenges of nephrocalcinosis in pregnancy (six pregnancies in four patients). (21730211)
2012
12
Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case for. (22776973)
2012
13
Testicular nuclear receptor 4 (TR4) regulates UV light-induced responses via Cockayne syndrome B protein-mediated transcription-coupled DNA repair. (21918225)
2011
14
Pulmonary marginal zone B-cell lymphoma of MALT type--what is a prognostic factor and which is the optimal treatment, operation, or chemotherapy?: Consortium for Improving Survival of Lymphoma (CISL) study. (20024551)
2010
15
The association of MHC class I proteins with the 2B4 receptor inhibits self-killing of human NK cells. (20164429)
2010
16
Zoonotic babesiosis: overview of the disease and novel aspects of pathogen identity. (21771506)
2010
17
The role of Endothelin-1 in obstructive sleep apnea syndrome and pulmonary arterial hypertension: pathogenesis and Endothelin-1 antagonists. (20156159)
2010
18
Docosahexaenoic acid neurolipidomics. (19804838)
2010
19
Impact of maternal periconceptional overnutrition on fat mass and expression of adipogenic and lipogenic genes in visceral and subcutaneous fat depots in the postnatal lamb. (20861234)
2010
20
Total and fetal cell-free DNA analysis in maternal blood as markers of placental insufficiency in intrauterine growth restriction. (19816026)
2009
21
Multifocal brain metastases in clear cell renal cell carcinoma with complete response to sunitinib. (19996660)
2009
22
Activation of telomerase and cyclooxygenase-2 in PDGF and FGF inhibition of C2-ceramide-induced apoptosis. (18932216)
2009
23
Diagnosis and treatment of adult growth hormone deficiency (aGHD) resulting from brain injury--role of aGHD]. (19110756)
2008
24
The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. (18559522)
2008
25
Immune evasion and immunosuppression by Anaplasma phagocytophilum, the causative agent of tick-borne fever of ruminants and human granulocytic anaplasmosis. (17275372)
2008
26
GLUT1 deficiency with delayed myelination responding to ketogenic diet. (17675029)
2007
27
Paraneoplastic Raynaud phenomenon with digital necrosis associated with hyperhomocysteinemia and antiphospholipid antibodies. (17938361)
2007
28
Ischemia-related changes of glial-derived neurotrophic factor and phosphatidylinositol 3-kinase in the hippocampus: their possible correlation in astrocytes. (16412399)
2006
29
Video-EEG recordings in idiopathic generalized epilepsy, including juvenile myoclonic epilepsy. (16529645)
2006
30
Polymorphisms in the SLC2A2 (GLUT2) gene are associated with the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. (15983230)
2005
31
Methylation of hMLH1 gene promoter in gastric carcinoma with microsatellite instability]. (15757526)
2005
32
Hereditary and acquired defects in the fibrinolytic system associated with thrombosis. (12627665)
2003
33
Mouse Leydig tumor cells produce C-19 steroids, including testosterone. (12628687)
2003
34
Cell-mediated immune responses to GAD and beta-casein in type 1 diabetes mellitus in Thailand. (11850100)
2002
35
Ryanodine receptor point mutant E4032A reveals an allosteric interaction with ryanodine. (11226332)
2001
36
Comparison between rest technetium-99m-tetrofosmin and rest-redistribution thallium-201 SPECT in stable patients with healed myocardial infarction. (11711902)
2001
37
Genomewide search in Canadian families with inflammatory bowel disease reveals two novel susceptibility loci. (10777714)
2000
38
Rectal epithelial apoptosis in familial adenomatous polyposis patients treated with sulindac. (10562579)
1999
39
Replication of damaged DNA: molecular defect in xeroderma pigmentosum variant cells. (10556591)
1999
40
Chromosome 15q11-13 region and the autistic disorder. (9678411)
1998
41
Three polymorphisms associated with low hepatic lipase activity are common in African Americans. (9741704)
1998
42
IL-12 receptor (IL-12R) expression and accumulation of IL-12R beta 1 and IL-12R beta 2 mRNAs in CD4+ T cells by costimulation with B7-2 molecules. (9469420)
1998
43
Tinea capitis. (8822034)
1996
44
Chondrolysis and avascular necrosis: complications of slipped capital femoral epiphysis. (8866280)
1996
45
Duplication of 10 nucleotides in the erythroid band 3 (AE1) gene in a kindred with hereditary spherocytosis and band 3 protein deficiency (band 3PRAGUE). (8282779)
1994
46
Influence of growth factors on the plasminogen activator activity of avian granulosa cells from follicles at different maturational stages of preovulatory development. (8148037)
1993
47
Lymphogranuloma venereum, chancroid, and granuloma inguinale. (2687744)
1989
48
The role of the mesangial cell in proliferative glomerulonephritis. (4573358)
1973
49
50

Variations for Pfeiffer Syndrome

About this section

UniProtKB/Swiss-Prot genetic disease variations for Pfeiffer Syndrome:

67 (show all 19)
id Symbol AA change Variation ID SNP ID
1FGFR1p.Pro252ArgVAR_004111
2FGFR2p.Ser252TrpVAR_004115
3FGFR2p.Cys278PheVAR_004121
4FGFR2p.Trp290CysVAR_004124
5FGFR2p.Asp321AlaVAR_004129
6FGFR2p.Thr341ProVAR_004135
7FGFR2p.Cys342ArgVAR_004137
8FGFR2p.Cys342SerVAR_004138
9FGFR2p.Cys342TyrVAR_004139
10FGFR2p.Ala344ProVAR_004141
11FGFR2p.Ser351CysVAR_004143
12FGFR2p.Val359PheVAR_004146
13FGFR2p.Ala172PheVAR_017259
14FGFR2p.Tyr340CysVAR_017269
15FGFR2p.Cys342GlyVAR_017270
16FGFR2p.Tyr375CysVAR_017275
17FGFR2p.Glu565GlyVAR_017277
18FGFR2p.Lys641ArgVAR_017278
19FGFR2p.Gly663GluVAR_017280

Clinvar genetic disease variations for Pfeiffer Syndrome:

5 (show all 13)
id Gene Variation Type Significance SNP ID Assembly Location
1FGFR2NM_000141.4(FGFR2): c.1025G> A (p.Cys342Tyr)single nucleotide variantPathogenicrs121918487GRCh37Chr 10, 123276892: 123276892
2FGFR2NM_000141.4(FGFR2): c.1024T> C (p.Cys342Arg)single nucleotide variantPathogenicrs121918488GRCh37Chr 10, 123276893: 123276893
3FGFR2NM_000141.4(FGFR2): c.1021A> C (p.Thr341Pro)single nucleotide variantPathogenicrs121918495GRCh37Chr 10, 123276896: 123276896
4FGFR2NM_000141.4(FGFR2): c.870G> C (p.Trp290Cys)single nucleotide variantPathogenicrs121918499GRCh37Chr 10, 123279562: 123279562
5FGFR2NM_000141.4(FGFR2): c.817_819delGAC (p.Asp273del)deletionPathogenicrs121918503GRCh37Chr 10, 123279613: 123279615
6FGFR2NM_000141.4(FGFR2): c.799T> C (p.Ser267Pro)single nucleotide variantPathogenicrs121918505GRCh37Chr 10, 123279633: 123279633
7FGFR2FGFR2, IVSAS, G-A, -1single nucleotide variantPathogenic
8FGFR2FGFR2, 10-BP DEL/3-BP INS, NT952indelPathogenic
9FGFR2NM_000141.4(FGFR2): c.870G> T (p.Trp290Cys)single nucleotide variantPathogenicrs121918499GRCh37Chr 10, 123279562: 123279562
10FGFR2NM_000141.4(FGFR2): c.1694A> C (p.Glu565Ala)single nucleotide variantPathogenicrs121918506GRCh37Chr 10, 123256215: 123256215
11FGFR2FGFR2, IVSDS, A-G, +3single nucleotide variantPathogenic
12FGFR2NM_000141.4(FGFR2): c.962A> C (p.Asp321Ala)single nucleotide variantPathogenicrs121918510GRCh37Chr 10, 123276955: 123276955
13FGFR1NM_023110.2(FGFR1): c.755C> G (p.Pro252Arg)single nucleotide variantPathogenicrs121909627GRCh37Chr 8, 38282208: 38282208

Expression for genes affiliated with Pfeiffer Syndrome

About this section
Search GEO for disease gene expression data for Pfeiffer Syndrome.

Pathways for genes affiliated with Pfeiffer Syndrome

About this section

Pathways related to Pfeiffer Syndrome according to GeneCards Suite gene sharing:

(show all 33)
idSuper pathwaysScoreTop Affiliating Genes
19.9FGFR1, FGFR2, FGFR3
29.9FGFR1, FGFR2, FGFR3
39.6BGLAP, RUNX2, TWIST1
49.5FGF10, FGF8, FGFR1, FGFR3
59.5ALPL, FGFR1, FGFR3, RUNX2
69.5CD40LG, COL1A1, COL3A1
79.5BGLAP, COL1A1, RUNX2
89.4BGLAP, FGFR1, FGFR2, RUNX2
99.4FGF8, FGFR1, FGFR2, FGFR3, TWIST1
109.3FGF7, FGFR1, FGFR2, FGFR3
119.2CD40LG, CR2, TNFRSF8
129.0CD40LG, COL3A1, TNFRSF8
13
Show member pathways
9.0FGF10, FGF7, FGF8, FGFR1, FGFR2
148.9BGLAP, COL1A1, FOSL1, RUNX2
158.9BGLAP, FGF10, FGF8, RUNX2, SP7
16
Show member pathways
8.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
17
Show member pathways
8.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
188.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
19
Show member pathways
8.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
20
Show member pathways
8.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
21
Show member pathways
8.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
22
Show member pathways
8.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
23
Show member pathways
8.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
24
Show member pathways
8.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
25
Show member pathways
8.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
26
Show member pathways
8.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
278.7FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
28
Show member pathways
8.5CD40LG, FGF10, FGF7, FGF8, FGFR1, FGFR2
298.2COL1A1, FGF10, FGF7, FGF8, FGFR1, FGFR2
30
Show member pathways
8.0COL1A1, COL3A1, FGF10, FGF7, FGF8, FGFR1
31
Show member pathways
7.7CD40LG, FGF10, FGF7, FGF8, FGFR1, FGFR2
32
Show member pathways
7.2CD40LG, FGF10, FGF7, FGF8, FGFR1, FGFR2
33
Show member pathways
6.4CD40LG, COL1A1, COL3A1, FGF10, FGF7, FGF8

GO Terms for genes affiliated with Pfeiffer Syndrome

About this section

Biological processes related to Pfeiffer Syndrome according to GeneCards Suite gene sharing:

(show top 50)    (show all 65)
idNameGO IDScoreTop Affiliating Genes
1fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex developmentGO:003560710.8FGFR1, FGFR2
2mesenchymal cell differentiation involved in lung developmentGO:006091510.8FGF10, FGFR2
3mammary gland bud formationGO:006061510.8FGF10, FGFR2
4fibroblast growth factor receptor signaling pathway involved in mammary gland specificationGO:006059510.8FGF10, FGFR2
5lacrimal gland developmentGO:003280810.8FGF10, FGFR2
6lung-associated mesenchyme developmentGO:006048410.7FGFR1, FGFR2
7regulation of fibroblast growth factor receptor signaling pathwayGO:004003610.6FGFR2, RUNX2
8limb bud formationGO:006017410.6FGF10, FGFR2
9regulation of odontogenesis of dentin-containing toothGO:004248710.6FGF8, RUNX2
10positive regulation of phospholipase activityGO:001051810.5FGFR1, FGFR2, FGFR3
11salivary gland morphogenesisGO:000743510.5FGF10, FGFR1
12organ inductionGO:000175910.5FGF10, FGF8, FGFR1
13positive regulation of DNA-templated transcription, initiationGO:200014410.4FOSL1, TWIST1
14positive regulation of MAPK cascadeGO:004341010.3FGF10, FGFR2, FGFR3
15secretion by lung epithelial cell involved in lung growthGO:006103310.3FGF10, FGF7
16regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signalingGO:006066510.3FGF10, FGF7
17otic vesicle formationGO:003091610.3FGF10, FGF8, FGFR2
18response to gravityGO:000962910.3BGLAP, FOSL1
19embryonic cranial skeleton morphogenesisGO:004870110.3FGFR2, RUNX2, TWIST1
20endochondral ossificationGO:000195810.2COL1A1, FGFR3, RUNX2
21digestive tract developmentGO:004856510.2COL3A1, FGF10, FGFR2
22orbitofrontal cortex developmentGO:002176910.1FGFR1, FGFR2
23bone mineralizationGO:003028210.1BGLAP, FGFR2, FGFR3
24bone developmentGO:006034810.0BGLAP, FGF8, FGFR2, TWIST1
25positive regulation of ERK1 and ERK2 cascadeGO:007037410.0FGF10, FGF8, FGFR2, FGFR3
26odontogenesisGO:004247610.0BGLAP, FGF8, FGFR2, TWIST1
27skeletal system morphogenesisGO:00487059.9COL1A1, FGFR1, FGFR2, RUNX2
28phosphatidylinositol phosphorylationGO:00468549.9FGF10, FGF7, FGF8
29positive chemotaxisGO:00509189.8FGF10, FGF7, FGF8
30Ras protein signal transductionGO:00072659.7FGF10, FGF8, FGFR1, FGFR2, FGFR3
31lung developmentGO:00303249.7FGF10, FGF8, FGFR1, FGFR2
32peptidyl-tyrosine phosphorylationGO:00181089.7FGF10, FGF7, FGF8, FGFR1
33ossificationGO:00015039.7BGLAP, COL1A1, RUNX2, TWIST1
34response to mechanical stimulusGO:00096129.4BGLAP, COL1A1, COL3A1, FOSL1
35branching involved in salivary gland morphogenesisGO:00604459.4FGF10, FGF7, FGF8, FGFR1, FGFR2
36wound healingGO:00420609.4COL1A1, COL3A1, FGF10, FGF7
37axon guidanceGO:00074119.4COL3A1, FGF10, FGFR1, FGFR2, FGFR3
38regulation of phosphatidylinositol 3-kinase signalingGO:00140669.3FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
39phosphatidylinositol-mediated signalingGO:00480159.3FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
40phosphatidylinositol-3-phosphate biosynthetic processGO:00360929.3FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
41activation of MAPKK activityGO:00001869.3FGF10, FGF7, FGF8, FGFR1, FGFR2
42epidermal growth factor receptor signaling pathwayGO:00071739.2FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
43fibroblast growth factor receptor signaling pathwayGO:00085439.2FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
44MAPK cascadeGO:00001659.1FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
45vascular endothelial growth factor receptor signaling pathwayGO:00480109.1FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
46insulin receptor signaling pathwayGO:00082869.1FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
47positive regulation of cell proliferationGO:00082848.8FGF10, FGF7, FGF8, FGFR1, FGFR3, RUNX2
48neurotrophin TRK receptor signaling pathwayGO:00480118.6FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3
49positive regulation of transcription from RNA polymerase II promoterGO:00459448.5FGF10, FGFR2, FOSL1, RUNX2, SP7, TWIST1
50innate immune responseGO:00450878.2FGF10, FGF7, FGF8, FGFR1, FGFR2, FGFR3

Molecular functions related to Pfeiffer Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1fibroblast growth factor-activated receptor activityGO:000500710.6FGFR2, FGFR3
2protein tyrosine kinase activityGO:00047139.3FGF7, FGFR1, FGFR2, FGFR3

Sources for Pfeiffer Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet